Osteoporosis International

, Volume 23, Issue 3, pp 797–809

Individualizing osteoporosis therapy

Review

Abstract

Guidelines for osteoporosis treatment are available; however, these guidelines suggest when to treat patients, without specific recommendations on what drugs to prescribe in various situations. Choice of osteoporosis therapy should be individualized based on consideration of the efficacy, safety, cost, convenience (i.e., dosing regimen and delivery), and other non-osteoporosis-related benefits associated with each agent. Bisphosphonates, administered orally or intravenously, should be considered first-line therapy, particularly in older patients, owing to their efficacy across multiple skeletal sites; however, there are potential short- and long-term safety concerns. Selective estrogen receptor modulators should be considered for younger postmenopausal women at greater risk for vertebral than hip fractures or as second-line therapy in women who cannot tolerate first-line therapies. Low-dose hormone therapy may be appropriate as prevention in women with menopausal symptoms at lower fracture risk. Calcitonin, with its relatively benign safety profile, may be appropriate for elderly women who may have difficulty following the complex dosing schedules of oral bisphosphonates. Anabolic therapies such as teriparatide should be considered for high-risk patients. Strontium ranelate (approved outside of North America), with both anabolic and antiresorptive properties, may be appropriate for women who cannot tolerate or are unable to take bisphosphonates. Denosumab is a monoclonal antibody appropriate for women at high fracture risk or who have failed other osteoporosis therapies, and may be considered in patients with renal insufficiency. It will be important to incorporate newer agents (e.g., bazedoxifene, tissue selective estrogen complex) into this individualized treatment paradigm to optimize clinical outcomes in patients with osteoporosis.

Keywords

Bisphosphonates Drug therapy Fracture Osteoporosis Postmenopause Selective estrogen receptor modulator 

References

  1. 1.
    Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRefGoogle Scholar
  2. 2.
    Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRefGoogle Scholar
  3. 3.
    International Osteoporosis Foundation (2010) Facts and statistics about osteoporosis and its impact. Available at http://www.iofbonehealth.org/facts-and-statistics.html. Accessed 2 November 2010
  4. 4.
    McCloskey E (2010) FRAX: identifying people at high risk of fracture. International Osteoporosis Foundation. Available at http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/FRAX-report-09.pdf. Accessed 12 January 2011
  5. 5.
    Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX® and its applications to clinical practice. Bone 44:734–743PubMedCrossRefGoogle Scholar
  7. 7.
    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRefGoogle Scholar
  8. 8.
    National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. Available at http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf. Accessed 23 July 2010
  9. 9.
    North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRefGoogle Scholar
  10. 10.
    Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRefGoogle Scholar
  11. 11.
    Institute of Medicine of the National Academies (2010) Dietary reference intakes for calcium and vitamin D. Available at http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. Accessed 7 July 2011
  12. 12.
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1):CD001155Google Scholar
  13. 13.
    Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1):CD004523Google Scholar
  14. 14.
    Chesnut CHI, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  15. 15.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  16. 16.
    Hochberg MC (2008) Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Curr Osteoporos Rep 6:89–94PubMedCrossRefGoogle Scholar
  17. 17.
    Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237–245PubMedCrossRefGoogle Scholar
  18. 18.
    Pazianas M, Epstein S, Zaidi M (2009) Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials 4:122–130PubMedCrossRefGoogle Scholar
  19. 19.
    Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44:758–765PubMedCrossRefGoogle Scholar
  20. 20.
    Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25–34PubMedCrossRefGoogle Scholar
  21. 21.
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213PubMedGoogle Scholar
  22. 22.
    Novartis Pharmaceuticals Corporation (2009) RECLAST (zoledronic acid) injection, solution for intravenous use [package insert]. Novartis Pharmaceuticals Corporation, East HanoverGoogle Scholar
  23. 23.
    Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD (2006) Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 29:1133–1152PubMedCrossRefGoogle Scholar
  24. 24.
    Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755–763PubMedCrossRefGoogle Scholar
  25. 25.
    Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18–23PubMedGoogle Scholar
  26. 26.
    Dell R, Greene D, Ott S, Silverman S, Eisemon E, Funahashi T, Adams A (2010) A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. J Bone Mineral Res 25:1201Google Scholar
  27. 27.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRefGoogle Scholar
  28. 28.
    Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122:S33–S45PubMedCrossRefGoogle Scholar
  29. 29.
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRefGoogle Scholar
  30. 30.
    Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10:118–122PubMedCrossRefGoogle Scholar
  31. 31.
    Lewiecki EM, Silverman SL (2006) Redefining osteoporosis treatment: who to treat and how long to treat. Arq Bras Endocrinol Metabol 50:694–704PubMedCrossRefGoogle Scholar
  32. 32.
    Cole Z, Dennison E, Cooper C (2008) Update on the treatment of post-menopausal osteoporosis. Br Med Bull 86:129–143PubMedCrossRefGoogle Scholar
  33. 33.
    Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581PubMedCrossRefGoogle Scholar
  34. 34.
    Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582–3590PubMedCrossRefGoogle Scholar
  35. 35.
    Gnant M (2010) Can oral bisphosphonates really reduce the risk of breast cancer in healthy women? J Clin Oncol 28:3548–3551PubMedCrossRefGoogle Scholar
  36. 36.
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134PubMedCrossRefGoogle Scholar
  37. 37.
    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729–1738PubMedCrossRefGoogle Scholar
  38. 38.
    Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 21:817–828PubMedCrossRefGoogle Scholar
  39. 39.
    Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891–2897PubMedCrossRefGoogle Scholar
  40. 40.
    Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O’Connell D, Cranney A (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529–539PubMedCrossRefGoogle Scholar
  41. 41.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  42. 42.
    Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J (2006) Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113:2425–2434PubMedCrossRefGoogle Scholar
  43. 43.
    National Osteoporosis Guideline Group Osteoporosis. Clinical guideline for prevention and treatment. Executive Summary. Updated July 2010Google Scholar
  44. 44.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedCrossRefGoogle Scholar
  45. 45.
    Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A, Ross PD (2006) Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int J Clin Pract 60:1394–1400PubMedCrossRefGoogle Scholar
  46. 46.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934PubMedCrossRefGoogle Scholar
  47. 47.
    Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, for the Bazedoxifene Study Group (2011) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int (in press)Google Scholar
  48. 48.
    de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567–576PubMedCrossRefGoogle Scholar
  49. 49.
    Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696PubMedCrossRefGoogle Scholar
  50. 50.
    Gennari L, Merlotti D, Nuti R (2010) Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging 5:19–29PubMedCrossRefGoogle Scholar
  51. 51.
    Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, Sriram U (2010) Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes. Menopause 18:17–22CrossRefGoogle Scholar
  52. 52.
    Pinkerton JV, Goldstein SR (2010) Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 17:642–653PubMedGoogle Scholar
  53. 53.
    Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16:1102–1108PubMedCrossRefGoogle Scholar
  54. 54.
    Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109–1115PubMedCrossRefGoogle Scholar
  55. 55.
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137PubMedCrossRefGoogle Scholar
  56. 56.
    Davidson M, Moffett A, Welty F, Simon J, Bolognese M, deMelo N, Wolter K, Proulx J, Radecki D (2005) Extraskeletal effects of lasofoxifene on postmenopausal women. J Bone Miner Res 20:S173, Abstract SA428Google Scholar
  57. 57.
    Fujita T, Fujii Y, Munezane H, Ohue M, Takagi Y (2010) Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. J Bone Miner Metab 28:477–484PubMedCrossRefGoogle Scholar
  58. 58.
    Lewiecki EM (2007) Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16:1663–1672PubMedCrossRefGoogle Scholar
  59. 59.
    Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92:1045–1052PubMedCrossRefGoogle Scholar
  60. 60.
    Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G (2009) Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92:1025–1038PubMedCrossRefGoogle Scholar
  61. 61.
    Pickar JH, Yeh I-T, Bachmann G, Speroff L (2009) Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92:1018–1024PubMedCrossRefGoogle Scholar
  62. 62.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH (2010) A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17:281–289PubMedCrossRefGoogle Scholar
  63. 63.
    Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S (2010) Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause 17:1221–1222, Abstract S-21Google Scholar
  64. 64.
    Silverman SL (2003) Calcitonin. Endocrinol Metab Clin North Am 32:273–284PubMedCrossRefGoogle Scholar
  65. 65.
    Chesnut CHI, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 109:267–276PubMedCrossRefGoogle Scholar
  66. 66.
    Novartis Pharma S.A.S. (2006) Miacalcin® (calcitonin-salmon) nasal spray [package insert]. Novartis Pharma S.A.S, HuningueGoogle Scholar
  67. 67.
    Miller PD (2008) Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:849–868PubMedCrossRefGoogle Scholar
  68. 68.
    Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C (2010) Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 51:460–471PubMedGoogle Scholar
  69. 69.
    TransPharma Medical (2011) TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disease [press release]. Available at http://www.news-medical.net/news/20110111/TransPharma-reports-positive-results-from-ViaDerm-Calcitonin-Phase-1-trial-for-musculoskeletal-disorders.aspx
  70. 70.
    Chesnut CH III, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19:479–491PubMedCrossRefGoogle Scholar
  71. 71.
    Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703PubMedCrossRefGoogle Scholar
  72. 72.
    European Medicines Agency (2009) European Public Assessment Report (EPAR) FORSTEO. EPAR summary for the public.Google Scholar
  73. 73.
    Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65:532–539PubMedCrossRefGoogle Scholar
  74. 74.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1–34)rhPTH] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511PubMedCrossRefGoogle Scholar
  75. 75.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRefGoogle Scholar
  76. 76.
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRefGoogle Scholar
  77. 77.
    Lau AN, Ali SH, Sawka AM, Thabane L, Papaioannou A, Gafni A, Adachi JD (2008) Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet Disord 9:151PubMedCrossRefGoogle Scholar
  78. 78.
    Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl 1):S11–S15PubMedCrossRefGoogle Scholar
  79. 79.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRefGoogle Scholar
  80. 80.
    Meunier PJ, Roux C, Ortolani S, az-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663–1673PubMedCrossRefGoogle Scholar
  81. 81.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822PubMedCrossRefGoogle Scholar
  82. 82.
    O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (4):CD005326Google Scholar
  83. 83.
    Servier (2010) Protelos leaflet. Available at http://www.cercledesdiabetologues.com/Pro/Osteoporosis/Protelos/Protelos.aspx?id=655. Accessed 27 October 2010
  84. 84.
    Amgen Inc. (2010) Prolia™ (denosumab), Injection, for subcutaneous use [package insert]. Amgen Inc., Thousand OaksGoogle Scholar
  85. 85.
    Amgen Inc. (2010) Xgeva (denosumab) injection, for subcutaneous use [package insert]. Amgen Inc., Thousand OaksGoogle Scholar
  86. 86.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  87. 87.
    Miller P, Bolognese M, Lewiecki E, McClung M, Weinstein R, Ding B, Wagman R, San Martin J (2010) Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. J Bone Miner Res 24:A09001486Google Scholar
  88. 88.
    Papapoulos S, Bone HGI, Brandi ML, Brown JP, Chapurlat RD, Czerwinski E, Daizadeh N, Grauer A, Haller C, Krieg MA, Libanati C, Man Z, Mellstrom D, Radominski SC, Reginster JYL, Resch H, Roman Ivorra JA, Roux C, Cummings SR (2010) Four years of denosumab exposure in women with postmenopausal osteoporosis: results from the first year extension of the FREEDOM trial. Presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research, 15–19 October 2010, Toronto, Ontario, CanadaGoogle Scholar
  89. 89.
    Miller PD (2009) Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 7:18–22PubMedCrossRefGoogle Scholar
  90. 90.
    Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA (2010) Oral salmon calcitonin—pharmacology in osteoporosis. Expert Opin Biol Ther 10:1617–1629PubMedCrossRefGoogle Scholar
  91. 91.
    Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y, Grazette L, San Martin J (2009) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Bone Miner Res. 2009;24(suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2167c9c3-703f-43d8-b76b-a35dcf86d465. Accessed 22 November 2010
  92. 92.
    Ideguchi H, Ohno S, Takase K, Ueda A, Ishigatsubo Y (2008) Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital. Osteoporos Int 19:1777–1783PubMedCrossRefGoogle Scholar
  93. 93.
    Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12–17PubMedCrossRefGoogle Scholar
  94. 94.
    Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25:976–982PubMedCrossRefGoogle Scholar
  95. 95.
    Proctor & Gamble Pharmaceuticals Inc (2007) ACTONEL® (risedronate sodium tablets) [package insert]. Proctor & Gamble Pharmaceuticals Inc, CincinnatiGoogle Scholar
  96. 96.
    Merck & Co., Inc (2007) FOSAMAX® (alendronate sodium) tablets and oral solution [package insert]. Merck & Co., Inc, Whitehouse StationGoogle Scholar
  97. 97.
    Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30(2):213–221PubMedCrossRefGoogle Scholar
  98. 98.
    American Association of Clinical Endocrinologists (2008) American Association of Clinical Endocrinologists (AACE) position statement on hormone replacement therapy (HRT) and cardiovascular risk. Available at http://www.aace.com/pub/pdf/guidelines/HRTCVRISKposition_statement.pdf
  99. 99.
    Arun B, Anthony M, Dunn B (2002) The search for the ideal SERM. Expert Opin Pharmacother 3:681–691PubMedCrossRefGoogle Scholar
  100. 100.
    National Health Service (2005) Strontium ranelate. Regional Drug and Therapeutics Centre New Drug Evaluation 69Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  1. 1.Cedars-Sinai Medical Center and University of CaliforniaLos AngelesUSA
  2. 2.Center for Clinical and Basic ResearchBallerupDenmark
  3. 3.Beverly HillsUSA

Personalised recommendations